Engineered donor cells take on childhood leukemia in first human test
NCT ID NCT04881240
First seen Jan 04, 2026 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This early-stage trial tests a new type of cell therapy for children and young adults up to age 21 with a form of leukemia (CD19-positive) that has returned or not responded to treatment. The therapy uses immune cells from a family donor that are engineered in a lab to recognize and attack leukemia cells. The main goal is to find a safe dose and understand side effects, including the risk of graft-versus-host disease. Up to 60 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor immune cells engineered to target leukemia cells (CD19-CAR T-cells)
What this could lead to
If it works, this could offer a new treatment option for children and young adults with leukemia that has come back or not responded to standard therapy.
What could go wrong
This is an early phase 1 trial, so the main goal is safety, not yet proof of effectiveness. There are risks of serious side effects like graft-versus-host disease or cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.